{
  "attach_pages": "5",
  "attach_size": "313",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201806141155778453_1.pdf?1559743405000.pdf",
  "company_code": "80000134",
  "eitime": "2018-06-14 14:20:38",
  "extend": {},
  "info_code": "AP201806141155778453",
  "language": "0",
  "notice_date": "2018-06-14 00:00:00",
  "notice_title": "类风关III期临床启动，利妥昔多适应症研发进入尾声",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "BBB",
  "researcher": "王冯",
  "security": [
    {
      "market_uni": "1",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "复星医药",
      "short_name_ch": "复星医药",
      "short_name_cht": "復星醫藥",
      "short_name_en": "FOSUN PHARMA",
      "stock": "600196"
    }
  ],
  "short_name": "复星医药",
  "source_sample_name": "华金证券",
  "star": "1"
}